White & Case, AZB, Sullivan, Cyril Amarchand Mangaldas act on Sun Pharma's $11.75 billion acquisition of Organon

Sun Pharmaceutical Industries Limited has acquired Organon & Co in an all‑cash deal, valuing Organon at $11.75 billion.

The acquisition will be made through Sun Pharmaceutical Holdings a U.S. subsidiary of Sun Pharma.

According to the release after this deal, Sun Pharma will one of the 25 largest pharma companies in the world with a $12.4 Billion revenue.

https://sunpharma.com/wp-content/uploads/2026/04/Press-Release-Sun-Pharma-signs-Definitive-Agreement-to-Acquire-Organon.pdf

AZB & Partners and White & Case are advising Sun Pharma on this acquisition.

Cyril Amarchand Mangaldas is advising Organon on Indian law aspects of the acquisition.

The transaction team is led by Ruetveij Pandya (Partner) and Saloni Shroff (Partner), with assistance from Abhilasha Malpani (Principal Associate), Associates Sajith Anjickal, Chelsea Sawlani, Neelanshi Gupta, Simran Srivastava, and Shravan Subramanian.

Rishabh Shroff (Partner, Co-Head - Private Client and Head - International Business Development) is providing strategic inputs and guidance.

Meeta Kurpad (Partner), with support from Manasvin Andra (Associate), is advising on financing aspects of the transaction.

Sullivan & Cromwell LLP is serving as legal advisor to Organon.

US-based Organon & Co. a global healthcare company, with diverse portfolio across women’s health, biosimilars, and therapies and products for a wide range of conditions and diseases.

Headquartered in India, Sun Pharma is the fourth largest specialty generic pharmaceutical company worldwide. Sun Pharma operates in more than 100 countries and has a global revenue of around US$ 6.2 billion. The company is supported by 41 manufacturing facilities and is known for providing high-quality, affordable medicines across various therapeutic areas.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.